Research programme: gestational and type 2 diabetes diagnostics - MaRS Innovation/Johnson & Johnson/University of Toronto

Drug Profile

Research programme: gestational and type 2 diabetes diagnostics - MaRS Innovation/Johnson & Johnson/University of Toronto

Latest Information Update: 16 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Toronto
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Gestational diabetes; Type 2 diabetes mellitus

Most Recent Events

  • 12 Jan 2015 Early research in Diagnostic tests in Canada (unspecified route)
  • 12 Jan 2015 Early research in Gestational diabetes (Diagnosis) in Canada (unspecified route)
  • 12 Jan 2015 Early research in Type-2 diabetes mellitus (Diagnosis) in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top